Shou C - Search Results

1

Development of a novel albumin-based and maleimidopropionic acid-conjugated peptide with prolonged half-life and increased in vivo anti-tumor efficacy.

Feng J, Zhao C, Wang L, Qu L, Zhu H, Yang Z, An G, Tian H, Shou C. Feng J, et al. Among authors: shou c. Theranostics. 2018 Mar 7;8(8):2094-2106. doi: 10.7150/thno.22069. eCollection 2018. Theranostics. 2018. PMID: 29721065 Free PMC article.

2

The effect of antibody against vascular endothelial growth factor on tumor growth and metastasis.

Wang G, Dong Z, Xu G, Yang Z, Shou C, Wang N, Liu T. Wang G, et al. Among authors: shou c. J Cancer Res Clin Oncol. 1998;124(11):615-20. doi: 10.1007/s004320050223. J Cancer Res Clin Oncol. 1998. PMID: 9860290

3

[The effect of antibody against vascular endothelial growth factor (VEGF) on tumor metastasis].

Wang G, Yang Z, Shou C. Wang G, et al. Among authors: shou c. Zhonghua Zhong Liu Za Zhi. 1997 Nov;19(6):407-9. Zhonghua Zhong Liu Za Zhi. 1997. PMID: 10920868 Chinese.

4

[Inhibition of tumor growth by a peptide fusion protein binding to vascular endothelial growth factor receptor Flt-1].

Lei H, Shou C, Wu J, Liu X, He L, Liu M, Guo Q, Jiang B. Lei H, et al. Among authors: shou c. Zhonghua Yi Xue Za Zhi. 2002 Oct 10;82(19):1342-5. Zhonghua Yi Xue Za Zhi. 2002. PMID: 12509940 Chinese.

5

Suppression of tumor growth and metastasis by a VEGFR-1 antagonizing peptide identified from a phage display library.

An P, Lei H, Zhang J, Song S, He L, Jin G, Liu X, Wu J, Meng L, Liu M, Shou C. An P, et al. Among authors: shou c. Int J Cancer. 2004 Aug 20;111(2):165-73. doi: 10.1002/ijc.20214. Int J Cancer. 2004. PMID: 15197767

6

Overexpression of phosphatase of regenerating liver-3 in breast cancer: association with a poor clinical outcome.

Wang L, Peng L, Dong B, Kong L, Meng L, Yan L, Xie Y, Shou C. Wang L, et al. Among authors: shou c. Ann Oncol. 2006 Oct;17(10):1517-22. doi: 10.1093/annonc/mdl159. Epub 2006 Jul 27. Ann Oncol. 2006. PMID: 16873432 Free article.

7

Applications of novel monoclonal antibodies specific for synuclein-gamma in evaluating its levels in sera and cancer tissues from colorectal cancer patients.

Liu C, Guo J, Qu L, Bing D, Meng L, Wu J, Shou C. Liu C, et al. Among authors: shou c. Cancer Lett. 2008 Sep 28;269(1):148-58. doi: 10.1016/j.canlet.2008.04.037. Epub 2008 Jun 30. Cancer Lett. 2008. PMID: 18586385

8

Prognostic value of PRL-3 overexpression in early stages of colonic cancer.

Xing X, Peng L, Qu L, Ren T, Dong B, Su X, Shou C. Xing X, et al. Among authors: shou c. Histopathology. 2009 Feb;54(3):309-18. doi: 10.1111/j.1365-2559.2009.03226.x. Histopathology. 2009. PMID: 19236507

9

[Construction and expression of PRL-3 plasmid with C104S point mutation and CAAX deletion].

Li WJ, Xing XF, Qu LK, Meng L, Shou CC. Li WJ, et al. Beijing Da Xue Xue Bao Yi Xue Ban. 2009 Oct 18;41(5):516-20. Beijing Da Xue Xue Bao Yi Xue Ban. 2009. PMID: 19829665 Free article. Chinese.

10

PRL-3 promotes the motility, invasion, and metastasis of LoVo colon cancer cells through PRL-3-integrin beta1-ERK1/2 and-MMP2 signaling.

Peng L, Xing X, Li W, Qu L, Meng L, Lian S, Jiang B, Wu J, Shou C. Peng L, et al. Among authors: shou c. Mol Cancer. 2009 Nov 24;8:110. doi: 10.1186/1476-4598-8-110. Mol Cancer. 2009. PMID: 19930715 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

227 results

Search Page

Filters